AMENDED AND RESTATED DEVELOPMENT AND LICENSE AGREEMENT dated as of December 11, 2008 by and between BIOSPECIFICS TECHNOLOGIES CORP. (a Delaware corporation) and AUXILIUM PHARMACEUTICALS, INC. (a Delaware corporation)Development and License Agreement • December 18th, 2008 • Auxilium Pharmaceuticals Inc • Pharmaceutical preparations • New York
This AMENDED AND RESTATED DEVELOPMENT AND LICENSE AGREEMENT (this “Agreement”) dated the 11th day of December, 2008 is by and between BioSpecifics Technologies Corp., a corporation organized and existing under the laws of Delaware and having its principal office at 35 Wilbur Street, Lynbrook, New York 11563, and its Affiliates (“BTC”), and Auxilium Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware and having its principal office 40 Valley Stream Parkway, Malvern, PA 19355 (“Auxilium”). BTC and Auxilium shall sometimes be referred to herein individually as a “Party” and collectively as “Parties.”
James E. Fickenscher/CFO William Q. Sargent Jr./ VP IR Auxilium Pharmaceuticals, Inc. Auxilium Pharmaceuticals, Inc.Development and Commercialization Agreement • December 18th, 2008 • Auxilium Pharmaceuticals Inc • Pharmaceutical preparations
MALVERN, PA and New York, NY, (December 17, 2008)— Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) and Pfizer, Inc. (NYSE: PFE) announced today that they have entered into a strategic alliance for the development, commercialization and supply of XIAFLEX™ (clostridial collagenase for injection), a novel, first-in-class, late-stage biologic, for the treatment of Dupuytren’s contracture and Peyronie’s disease. Under the terms of the agreement, Pfizer will receive exclusive rights to commercialize XIAFLEX in the 27 member countries of the European Union (EU) and 19 other European and Eurasian countries. In addition, Pfizer will be primarily responsible for regulatory activities for XIAFLEX in these countries.
DEVELOPMENT, COMMERCIALIZATION AND SUPPLY AGREEMENT DATED AS OF DECEMBER 17, 2008 BY AND AMONG AUXILIUM PHARMACEUTICALS, INC. AND AUXILIUM INTERNATIONAL HOLDINGS, INC. AND PFIZER INC.Development, Commercialization and Supply Agreement • December 18th, 2008 • Auxilium Pharmaceuticals Inc • Pharmaceutical preparations • New York
This Development, Commercialization and Supply Agreement (this “Agreement”), dated as of December 17, 2008 (the “Effective Date”), is made by and among Auxilium Pharmaceuticals, Inc., a Delaware corporation, and Auxilium International Holdings, Inc., a Delaware corporation, (together referred to as “Auxilium”), and Pfizer, Inc., a Delaware corporation (“Pfizer”). Auxilium and Pfizer are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
